These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 23326440)
1. Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells. Hou L; Zhao X; Wang P; Ning Q; Meng M; Liu C PLoS One; 2013; 8(1):e53491. PubMed ID: 23326440 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of an Integrin α Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615 [TBL] [Abstract][Full Text] [Related]
3. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells. Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455 [TBL] [Abstract][Full Text] [Related]
4. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. Curnis F; Cattaneo A; Longhi R; Sacchi A; Gasparri AM; Pastorino F; Di Matteo P; Traversari C; Bachi A; Ponzoni M; Rizzardi GP; Corti A J Biol Chem; 2010 Mar; 285(12):9114-23. PubMed ID: 20064928 [TBL] [Abstract][Full Text] [Related]
5. The CNGRCLLII(KLAKLAK)2 peptide shows cytotoxicity against HUVECs by inducing apoptosis: An in vitro and in vivo study. Wang G; Yuan N; Huang S; Feng L; Han R; Zhang Y; Ren J; Meng M; Zhao X Tumour Biol; 2017 May; 39(5):1010428317701649. PubMed ID: 28475015 [TBL] [Abstract][Full Text] [Related]
6. A CD13-targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Zheng YB; Gong JH; Liu XJ; Li Y; Zhen YS Mol Carcinog; 2017 May; 56(5):1395-1404. PubMed ID: 27991698 [TBL] [Abstract][Full Text] [Related]
7. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma. Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238 [TBL] [Abstract][Full Text] [Related]
8. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity. Sheng W; Shang Y; Li L; Zhen Y Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279 [TBL] [Abstract][Full Text] [Related]
9. Selective phenylalanine to proline substitution for improved antimicrobial and anticancer activities of peptides designed on phenylalanine heptad repeat. Tripathi AK; Kumari T; Tandon A; Sayeed M; Afshan T; Kathuria M; Shukla PK; Mitra K; Ghosh JK Acta Biomater; 2017 Jul; 57():170-186. PubMed ID: 28483698 [TBL] [Abstract][Full Text] [Related]
10. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901 [TBL] [Abstract][Full Text] [Related]
12. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. Wang L; Shi J; Kim YS; Zhai S; Jia B; Zhao H; Liu Z; Wang F; Chen X; Liu S Mol Pharm; 2009; 6(1):231-45. PubMed ID: 19067525 [TBL] [Abstract][Full Text] [Related]
13. Cimicifuga dahurica extract inhibits the proliferation, migration and invasion of breast cancer cells MDA-MB-231 and MCF-7 in vitro and in vivo. Jia H; Wang X; Liu W; Qin X; Hu B; Ma Q; Lv C; Lu J J Ethnopharmacol; 2021 Sep; 277():114057. PubMed ID: 33771643 [TBL] [Abstract][Full Text] [Related]
14. Antiproliferative and antimetastatic characterization of an exo-heterocyclic androstane derivative against human breast cancer cell lines. Kulmány ÁE; Frank É; Kovács D; Kirisits K; Krupitza G; Neuperger P; Alföldi R; Puskás LG; Szebeni GJ; Zupkó I Biomed Pharmacother; 2021 Aug; 140():111728. PubMed ID: 34020244 [TBL] [Abstract][Full Text] [Related]
15. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis. Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226 [TBL] [Abstract][Full Text] [Related]
16. Dual function of RGD-modified VEGI-192 for breast cancer treatment. Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451 [TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Gründker C; Föst C; Fister S; Nolte N; Günthert AR; Emons G Breast Cancer Res; 2010; 12(4):R49. PubMed ID: 20630060 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Razak NA; Abu N; Ho WY; Zamberi NR; Tan SW; Alitheen NB; Long K; Yeap SK Sci Rep; 2019 Feb; 9(1):1514. PubMed ID: 30728391 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. Gupta P; Srivastava SK BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293 [TBL] [Abstract][Full Text] [Related]
20. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]